Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
MediPharm LabsTSX:LABS Current Ratio is 2.69 as of Jun. 2026, which is 25% below its 10-year median of 3.61. The stock has 4 warning signs investors should review. Among 996 Drug Manufacturers companies, MediPharm Labs ranks better than 64.96% on this metric.
The current ratio is a liquidity ratio that measures a company's ability to pay short-term obligations. It is calculated as a company's Total Current Assets divides by its Total Current Liabilities. MediPharm Labs's current ratio for the quarter that ended in Jun. 2026 was 2.69.
MediPharm Labs has a current ratio of 2.69. It generally indicates good short-term financial strength.
The historical rank and industry rank for MediPharm Labs's Current Ratio or its related term are showing as below:
TSX:LABS'
s Current Ratio Range Over the Past 10 Years
Min: 1.28 Med: 3.61 Max: 64
Current: 2.69
During the past 9 years, MediPharm Labs's highest Current Ratio was 64.00. The lowest was 1.28. And the median was 3.61.
TSX:LABS's Current Ratio is ranked better than 64.96% of 996
companies
in the Drug Manufacturers industry
Industry Median: 1.925
vs TSX:LABS: 2.69
MediPharm Labs (TSX:LABS) Current Ratio Explanation
The current ratio can give a sense of the efficiency of a company's operating cycle or its ability to turn its product into cash. Companies that have trouble getting paid on their receivables or have long inventory turnover can run into liquidity problems because they are unable to alleviate their obligations. Because business operations differ in each industry, it is always more useful to compare companies within the same industry.
Acceptable current ratios vary from industry to industry and are generally between 1 and 3 for healthy businesses.
The higher the current ratio, the more capable the company is of paying its obligations. A ratio under 1 suggests that the company would be unable to pay off its obligations if they came due at that point. While this shows the company is not in good financial health, it does not necessarily mean that it will go bankrupt - as there are many ways to access financing - but it is definitely not a good sign.
If all other things were equal, a creditor, who is expecting to be paid in the next 12 months, would consider a high current ratio to be better than a low current ratio, because a high current ratio means that the company is more likely to meet its liabilities which fall due in the next 12 months.
MediPharm Labs Current Ratio Related Terms
MediPharm Labs Current Ratio Historical Data
* Premium members only.
The historical data trend for MediPharm Labs's Current Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, MediPharm Labs's Current Ratio, along with its competitors' market caps and Current Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
MediPharm Labs Current Ratio vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, MediPharm Labs's Current Ratio distribution charts can be found below:
* The bar in red indicates where MediPharm Labs's Current Ratio falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
MediPharm Labs (TSX:LABS) has a Current Ratio of 2.69 as of Jun. 2026. This is 25% below median its historical median of 3.61. Over the past decade, MediPharm Labs' Current Ratio has ranged from 1.28 to 64.00. According to the industry distribution chart, MediPharm Labs ranks #349 out of 996 companies in the Drug Manufacturers industry, placing it in the top 35%.
Is MediPharm Labs' Current Ratio too high?
MediPharm Labs' current Current Ratio of 2.69 is 25% below median its 10-year median of 3.61. Over the past 10 years, this metric has ranged from a low of 1.28 to a high of 64.00. The Drug Manufacturers industry median Current Ratio is 1.93. MediPharm Labs' value of 2.69 is 39.7% above this industry median. Based on the distribution chart, MediPharm Labs ranks #349 out of 996 companies in the Drug Manufacturers industry, which is above the industry midpoint.
How does MediPharm Labs' Current Ratio compare to ZTS?
According to the Drug Manufacturers industry distribution chart, MediPharm Labs ranks #349 out of 996 companies for Current Ratio. This puts MediPharm Labs in the upper half of its industry. The industry median Current Ratio is 1.93. MediPharm Labs' value of 2.69 is 39.7% above this benchmark. Historically, MediPharm Labs' own Current Ratio has ranged from 1.28 to 64.00 over the past decade. While the company's 10-year median is 3.61 vs. the industry median of 1.93, MediPharm Labs has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Current Ratio for a Drug Manufacturers company?
The median Current Ratio among Drug Manufacturers companies is 1.93, based on 996 companies in the industry. Companies in the top quartile (top 25%) have a Current Ratio significantly above this median, while those in the bottom quartile fall well below. However, Current Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. MediPharm Labs's current Current Ratio of 2.69 is 39.7% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Current Ratio mean?
A high Current Ratio can signal that a stock is expensive relative to its fundamentals. For the Drug Manufacturers industry, the median Current Ratio is 1.93 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. MediPharm Labs's current Current Ratio is 2.69, which is 25% below median its own 10-year median of 3.61. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is MediPharm Labs stock overvalued right now?
Based on GuruFocus' analysis, MediPharm Labs (TSX:LABS) is currently considered Modestly Overvalued. The stock's GF Value™ is C$0.07, compared to a current price of C$0.08 — trading 14.3% above its estimated fair value. The current Current Ratio is 2.69, which is 25% below median its 10-year median of 3.61 and 39.7% above the Drug Manufacturers industry median of 1.93. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Current Ratio calculated?
Current Ratio is calculated from a company's financial statements. For MediPharm Labs (TSX:LABS), the current Current Ratio is 2.69 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
MediPharm Labs Corp and its subsidiaries produce cannabis, purified and pharmaceutical-like cannabis extracts, related derivative products, and cannabis-related medical information and services. Its operating subsidiaries hold cultivation, standard processing, and sale licences under the Cannabis Act (Canada), allowing the cultivation, sale, and distribution of cannabis oil, extracts, edibles, topicals, dried and fresh cannabis, and derivatives to authorized purchasers. Its subsidiary provides clinic services to Canadian patients requiring medical cannabis education and prescriptions. The company operates in one reportable segment, the production and sales of cannabis flower, and generates maximum revenue from Canada, with additional international sales.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
TSX:LABS has been successfully added to your 
